Growth Hormone Perturbations in Fibromyalgia: A Review

Kim Jones, Parimal Deodhar, Ashley Lorentzen, Robert (Rob) Bennett, Atulya (Atul) Deodhar

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Objective: Fibromyalgia (FM) is a syndrome characterized by chronic widespread pain, fatigue, disrupted sleep, depression, and physical deconditioning. In this article, we review the literature on the normal activity of the hypothalamic-pituitary-growth hormone-insulin-like growth factor-1 (HP-GH-IGF-1) axis and its perturbations in FM subjects. Methods: Studies included in this review were accessed through an English language search of Cochrane Collaboration Reviews. Keyword MeSH terms included "fibromyalgia," "growth hormone" (GH), or "insulin-like growth factor-1" (IGF-1). Results: Twenty-six studies enrolling 2006 subjects were reviewed. Overall, low levels of IGF-1 were found in a subgroup of subjects. Growth hormone stimulation tests often revealed a suboptimal response, which did not always correlate with IGF-1 levels. No consistent defects in pituitary function were found. Of the 3 randomized placebo controlled studies, only 9 months of daily injectable recombinant GH reduced FM symptoms and normalized IGF-1. Conclusions: These studies suggest that pituitary function is normal in FM and that reported changes in the HP-GH-IGF-1 axis are most likely hypothalamic in origin. The therapeutic efficacy of supplemental GH therapy in FM requires further study before any solid recommendations can be made.

Original languageEnglish (US)
Pages (from-to)357-379
Number of pages23
JournalSeminars in Arthritis and Rheumatism
Volume36
Issue number6
DOIs
StatePublished - Jun 2007

Fingerprint

Fibromyalgia
Somatomedins
Growth Hormone
Chronic Pain
Fatigue
Sleep
Language
Placebos
Depression
Injections
Therapeutics

Keywords

  • fibromyalgia
  • growth hormone (GH)
  • growth hormone releasing hormone (GHRH)
  • hypothalamus
  • insulin-like growth factor-1 (IGF-1)
  • pituitary
  • somatostatin

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Orthopedics and Sports Medicine
  • Rheumatology

Cite this

Growth Hormone Perturbations in Fibromyalgia : A Review. / Jones, Kim; Deodhar, Parimal; Lorentzen, Ashley; Bennett, Robert (Rob); Deodhar, Atulya (Atul).

In: Seminars in Arthritis and Rheumatism, Vol. 36, No. 6, 06.2007, p. 357-379.

Research output: Contribution to journalArticle

Jones, Kim ; Deodhar, Parimal ; Lorentzen, Ashley ; Bennett, Robert (Rob) ; Deodhar, Atulya (Atul). / Growth Hormone Perturbations in Fibromyalgia : A Review. In: Seminars in Arthritis and Rheumatism. 2007 ; Vol. 36, No. 6. pp. 357-379.
@article{cf99c5f7cdd14cc083d6539fa4a1ef3b,
title = "Growth Hormone Perturbations in Fibromyalgia: A Review",
abstract = "Objective: Fibromyalgia (FM) is a syndrome characterized by chronic widespread pain, fatigue, disrupted sleep, depression, and physical deconditioning. In this article, we review the literature on the normal activity of the hypothalamic-pituitary-growth hormone-insulin-like growth factor-1 (HP-GH-IGF-1) axis and its perturbations in FM subjects. Methods: Studies included in this review were accessed through an English language search of Cochrane Collaboration Reviews. Keyword MeSH terms included {"}fibromyalgia,{"} {"}growth hormone{"} (GH), or {"}insulin-like growth factor-1{"} (IGF-1). Results: Twenty-six studies enrolling 2006 subjects were reviewed. Overall, low levels of IGF-1 were found in a subgroup of subjects. Growth hormone stimulation tests often revealed a suboptimal response, which did not always correlate with IGF-1 levels. No consistent defects in pituitary function were found. Of the 3 randomized placebo controlled studies, only 9 months of daily injectable recombinant GH reduced FM symptoms and normalized IGF-1. Conclusions: These studies suggest that pituitary function is normal in FM and that reported changes in the HP-GH-IGF-1 axis are most likely hypothalamic in origin. The therapeutic efficacy of supplemental GH therapy in FM requires further study before any solid recommendations can be made.",
keywords = "fibromyalgia, growth hormone (GH), growth hormone releasing hormone (GHRH), hypothalamus, insulin-like growth factor-1 (IGF-1), pituitary, somatostatin",
author = "Kim Jones and Parimal Deodhar and Ashley Lorentzen and Bennett, {Robert (Rob)} and Deodhar, {Atulya (Atul)}",
year = "2007",
month = "6",
doi = "10.1016/j.semarthrit.2006.09.006",
language = "English (US)",
volume = "36",
pages = "357--379",
journal = "Seminars in Arthritis and Rheumatism",
issn = "0049-0172",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Growth Hormone Perturbations in Fibromyalgia

T2 - A Review

AU - Jones, Kim

AU - Deodhar, Parimal

AU - Lorentzen, Ashley

AU - Bennett, Robert (Rob)

AU - Deodhar, Atulya (Atul)

PY - 2007/6

Y1 - 2007/6

N2 - Objective: Fibromyalgia (FM) is a syndrome characterized by chronic widespread pain, fatigue, disrupted sleep, depression, and physical deconditioning. In this article, we review the literature on the normal activity of the hypothalamic-pituitary-growth hormone-insulin-like growth factor-1 (HP-GH-IGF-1) axis and its perturbations in FM subjects. Methods: Studies included in this review were accessed through an English language search of Cochrane Collaboration Reviews. Keyword MeSH terms included "fibromyalgia," "growth hormone" (GH), or "insulin-like growth factor-1" (IGF-1). Results: Twenty-six studies enrolling 2006 subjects were reviewed. Overall, low levels of IGF-1 were found in a subgroup of subjects. Growth hormone stimulation tests often revealed a suboptimal response, which did not always correlate with IGF-1 levels. No consistent defects in pituitary function were found. Of the 3 randomized placebo controlled studies, only 9 months of daily injectable recombinant GH reduced FM symptoms and normalized IGF-1. Conclusions: These studies suggest that pituitary function is normal in FM and that reported changes in the HP-GH-IGF-1 axis are most likely hypothalamic in origin. The therapeutic efficacy of supplemental GH therapy in FM requires further study before any solid recommendations can be made.

AB - Objective: Fibromyalgia (FM) is a syndrome characterized by chronic widespread pain, fatigue, disrupted sleep, depression, and physical deconditioning. In this article, we review the literature on the normal activity of the hypothalamic-pituitary-growth hormone-insulin-like growth factor-1 (HP-GH-IGF-1) axis and its perturbations in FM subjects. Methods: Studies included in this review were accessed through an English language search of Cochrane Collaboration Reviews. Keyword MeSH terms included "fibromyalgia," "growth hormone" (GH), or "insulin-like growth factor-1" (IGF-1). Results: Twenty-six studies enrolling 2006 subjects were reviewed. Overall, low levels of IGF-1 were found in a subgroup of subjects. Growth hormone stimulation tests often revealed a suboptimal response, which did not always correlate with IGF-1 levels. No consistent defects in pituitary function were found. Of the 3 randomized placebo controlled studies, only 9 months of daily injectable recombinant GH reduced FM symptoms and normalized IGF-1. Conclusions: These studies suggest that pituitary function is normal in FM and that reported changes in the HP-GH-IGF-1 axis are most likely hypothalamic in origin. The therapeutic efficacy of supplemental GH therapy in FM requires further study before any solid recommendations can be made.

KW - fibromyalgia

KW - growth hormone (GH)

KW - growth hormone releasing hormone (GHRH)

KW - hypothalamus

KW - insulin-like growth factor-1 (IGF-1)

KW - pituitary

KW - somatostatin

UR - http://www.scopus.com/inward/record.url?scp=34248651389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248651389&partnerID=8YFLogxK

U2 - 10.1016/j.semarthrit.2006.09.006

DO - 10.1016/j.semarthrit.2006.09.006

M3 - Article

C2 - 17224178

AN - SCOPUS:34248651389

VL - 36

SP - 357

EP - 379

JO - Seminars in Arthritis and Rheumatism

JF - Seminars in Arthritis and Rheumatism

SN - 0049-0172

IS - 6

ER -